Information Provided By:
Fly News Breaks for September 18, 2017
BEAT
Sep 18, 2017 | 09:12 EDT
Dougherty analyst Gene Mannheimer refuted the "short" report published by a boutique research firm regarding BioTelemetry, stating that the report doesn't appear to consider an anticipated 2% reimbursement increase that should help the company see 10% growth in 2018 even if volumes fall short of double-digit growth. The analyst, who expects volume increases from both core BioTelemetry and newly acquired LifeWatch in absolute terms, maintains a Buy rating and $40 price target on the stock, which declined about 12% on Friday.
News For BEAT From the Last 2 Days
There are no results for your query BEAT
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.